Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is
sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx
within normal range at 12 months post-dosing in postmenopausal early breast cancer patients
receiving additional treatment with non-steroidal aromatase inhibitors.